Inflammation develops in response to foreign agents or injuries and is crucial to the healing process. However, persistent unresolved inflam mation can contribute to the development of can cer (Coussens et al., 2013) . Despite the wealth of information implicating inflammation in tumor development, the specific role of different cells, especially myeloid cells, in this process remains largely unclear. Myeloid cells are an important component of inflammation. There is now ample evidence of abnormalities in the myeloid com partment in cancer, which manifests in inhi bition of differentiation of DCs, polarization of macrophages (Ms) toward M2 functional state, and dramatic expansion of myeloidderived suppressor cells (MDSCs; Gabrilovich et al., 2012) . MDSCs represent a heterogeneous population of pathologically activated myeloid cells that includes precursors of neutrophils (polymorpho nuclear neutrophils [PMNs] ), Ms, DCs, and cells at earlier stages of myeloid cell differentia tion (Gabrilovich and Nagaraj, 2009; Peranzoni et al., 2010; Youn et al., 2012) . In mice, these cells are defined as Gr1 + CD11b + cells with the
RESULTS

S100A9-positive myeloid cells in tissues of patients with inflammation or cancers
Although parameters for detection of MDSCs in peripheral blood of cancer patients by flow cytometry are well estab lished, immunohistochemical detection of these cells in tissues has not been developed. Thus, we designed a double staining protocol of tissues for the CD33 myeloid marker and S100A9 using confocal microscopy ( Fig. 1 A) . S100A9 was used for MDSC detection because this protein is directly im plicated in accumulation of these cells in cancer and is shown as an MDSC marker in peripheral blood of cancer patients. The presence of CD33 + S100A9 + was then assessed in skin of patients with melanoma and basal cell carcinoma (BCC), as well as in patients with several inflammatory skin diseases (Fig. 1 B) . No increase in the presence of these cells was found in patients with lichen planus or psoriasis as compared with controls. In contrast, patients with spongiotic dermatitis (ec zema) had significantly (P = 0.001) higher numbers of CD33 + S100A9 + cells in skin. The presence of these cells was a little higher in patients with BCC. Patients with melanoma had a dramatic increase in number of these cells (Fig. 1 C) . CD33 + S100A9 + cells can represent not only IMCs or MDSCs but also PMNs because the expression of S100A9 is retained in these cells as opposed to Ms or DCs Ehrchen et al., 2009; Srivastava et al., 2012; Markowitz and Carson, 2013) . Therefore, we evaluated the presence of PMNs in skin using a specific marker neutrophil elastase. No differ ence in the number of PMNs was found for any of the condi tions except in patients with melanoma ( Fig. 1 C) . CD163 + Ms were modestly increased in skin of patients with ec zema, BCC, and melanoma ( Fig. 1 C) . We also evaluated colon tissue samples from a cohort of patients with ulcerative colitis with evidence of dysplasia and colon from cancer patients. Dramatic (>10fold) increase in the presence of CD33 + S100A9 + cells was found in tissues from patients with colitis and colon cancer, whereas the number of PMNs and Ms increased less than twofold (Fig. 1 E) . Lichen planus and psoriasis are not associated with the development of skin cancer, whereas his tory of eczema is an independent predictor of BCC (Dyer et al., 2012) . Ulcerative colitis, especially in patients with dys plasia, is associated with colon cancer (Dalgleish and O'Byrne, 2006; Dyson and Rutter, 2012) . These results indicate that the population of CD33 + S100A9 + cells represented by IMCs or MDSCs is dramatically increased in select inflammatory con ditions, which are associated with an increased risk for devel oping cancer.
The role of IMCs in tumor development
Next we asked what role, if any, these cells can play in tumor development. To address this question, we used mice with overexpression of S100A9 protein in hematopoietic cells (S100A9Tg mice; Cheng et al., 2008) . S100A9Tg mice (FVB/N background) had no detectable abnormalities during the first months of life (Chen et al., 2013) . Compared with WT mice, S100A9Tg mice expressed higher amounts of S100A9 protein recognition of polymorphonuclear (PMNMDSC) and mono nuclear (MMDSC) subsets based on the expression of Ly6C and Ly6G markers (Fridlender et al., 2009; Peranzoni et al., 2010; Brandau et al., 2011; Youn et al., 2012) . MDSCs are char acterized by a potent immunesuppressive activity and the ability to promote tumor angiogenesis, tumor cell invasion, and metastases (Bierie and Moses, 2010; Gabrilovich et al., 2012; Talmadge and Gabrilovich, 2013) . In tumorfree mice, cells with the same phenotype represent immature myeloid cells (IMCs) lacking immunesuppressive activity. Expansion of MDSCs is considered a consequence of tumor progression. However, in recent years, it has become clear that the cells with phenotypes and functions attributed to MDSCs are readily detectable in different conditions associated with chronic inflammation not directly linked to cancer (Cuenca et al., 2011; Nagaraj et al., 2013) . We hypothesize that these cells can contribute to tumor development associated with inflamma tion. Understanding the role of specific components of inflammation in tumor development is difficult because of the fact that inflammation is a multicomponent complex pro cess. To address this question, we focused on S100A9 protein. This is the member of the S100 family of Ca 2+ binding pro teins with diverse biological activity, including chemotaxis of myeloid cells, fatty acid transport, production of reactive oxy gen species, etc. (Markowitz and Carson, 2013) . Expression of S100A9 together with its dimerization partner S100A8 is found predominantly in cells of the myeloid lineage. Differ entiation of myelocytes/granulocytes is associated with an increase of S100A8/A9 expression, whereas differentiation of Ms and DCs is associated with loss of their expression Ehrchen et al., 2009; Srivastava et al., 2012; Markowitz and Carson, 2013) . Cells of the lymphoid lineage do not express these proteins. We and others have previously found that accumulation of MDSCs and inhibition of DC differentiation in cancer were closely associated with up regulation of S100A8/A9 (Cheng et al., 2008; Sinha et al., 2008; Ichikawa et al., 2011) . The expansion of MDSCs was significantly reduced in S100A9deficient mice treated with complete Freund's adjuvant or tumorbearing mice (Cheng et al., 2008) . In contrast, overexpression of S100A9 in mice resulted in accumulation of cells with MDSC phenotype (Chen et al., 2013) . Furthermore, these data were consistent with a recent report that DCs derived from S100A9deficient mice induced stronger response of allogeneic T cells (Shimizu et al., 2011) . In recent years, S100A9 was identified as a marker of MDSCs in peripheral blood of cancer patients and tumor bearing mice (Feng et al., 2012; Källberg et al., 2012; Zhao et al., 2012) . We asked whether regulation of S100A9 level in myeloid cells could be used to dissect the possible role of MDSCs during early stages of tumor development. Here, we report that cells with the MDSC phenotype accumulate in tissues of patients with precancerous inflammation and that these cells play a major role in tumor development in mice. Importantly, this effect was not directly mediated by immune suppressive mechanisms but by the recruitment of IL17-producing CD4 + T cells. Control and colon cancer groups included six patients and colitis group included five patients. (C and E) Mean and SD are shown. The differences from control: *, P < 0.05; **, P < 0.01; ***, P < 0.001. a malignant stage (Humble et al., 2005) . In C57BL/6 mice, skin tumor formation was induced by a single application of the carcinogen 7,12dimethylbenz(a)anthracene (DMBA), fol lowed by 12wk topical treatment with TPA.
Topical treatment of WT mice with TPA for 4 wk did not result in detectable levels of S100A9 in skin. In contrast, in BM, spleen, LNs, and lung, but not in skin or liver (Fig. 2 A) . Two models of skin carcinogenesis were used. Tg.AC mice (also FVB/N) express the mutant v-h-ras transgene under the globin promoter. When treated topically with the tumor promoter 12Otetradecanoylphorbol13acetate (TPA), Tg.AC mice develop multiple papillomas, some of which progress to untreated S100A9Tg mice had a low level of the protein, and TPA treatment of S100A9Tg mice caused a substantial increase in the amount of the protein (Fig. 2 B) . Although treatment of WT mice with TPA resulted in only a small in crease in the number of Gr1 + cells in skin (evaluated by immunohistochemistry [IHC] ), in S100A9Tg mice these cells increased approximately threefold (P < 0.01; Fig. 2 , C and D). Evaluation of cells derived from skin sample digests by flow cytometry revealed that all the Gr1 + cells also ex pressed CD11b and thus have phenotypic markers of MDSCs. The proportion of Ly6C hi Ly6G  monocytic cells among CD11b + cells in TPAtreated skin was the same in WT and S100A9Tg mice, whereas the proportion of Ly6C lo Ly6G + granulocytic cells was significantly higher in S100A9Tg than in WT mice (Fig. 2 E) . No differences in the numbers of F4/80 + Ms between WT and S100A9Tg skin were found ( Fig. 2 F) , whereas the number of CD11c + skin DCs was sig nificantly lower in both acetone and TPAtreated S100A9Tg than in WT mice (Fig. 2 G) . We investigated whether the dra matic increase of granulocytic cells in the skin of S100A9Tg mice was the result of their expansion in BM. There was a slight increase in the presence of these cells in BM of TPA treated S100A9Tg versus WT mice, but the ratio between granulocytic and monocytic subsets of IMCs was the same (Fig. 2, H and I ). These data indicate that, consistent with previous observations (Cheng et al., 2008) , the overexpression of S100A9 in myeloid progenitors did not cause expansion of myeloid cells but rather diverted their differentiation toward immature granulocytic cells. As a result, topical application of TPA in S100A9Tg mice caused substantial accumulation of IMCs with granulocytic phenotype, whereas the presence of Ms and DCs was either unchanged or decreased.
To study skin carcinogenesis, the S100A9Tg mice were crossed with homozygous Tg.AC mice, and hemizygous monotransgenic (Tg.AC) and bitransgenic (S100A9; Tg.AC) littermates were topically treated twice weekly for 6 wk with the tumor promoter TPA. Papillomas developed much faster and at significantly (P < 0.001) higher numbers in bitrans genic mice expressing S100A9Tg than in monotransgenic mice (Fig. 3 A) . S100A9 expression could be induced in ke ratinocytes under inflammatory conditions (Sorenson et al., 2012) . To clarify the role of infiltrating BMderived cells in increased tumorigenesis in S100A9Tg mice, lethally irradi ated Tg.AC mice were reconstituted with BM from WT or S100A9Tg mice, and papilloma formation was similarly eval uated after TPA treatment. Recipients of S100ATg BM developed significantly (P < 0.05) more papillomas than re cipients of BM from WT mice (Fig. 3 B) , demonstrating that upregulation of S100A9 in BMderived hematopoietic cells was responsible for increased tumor formation. To confirm a specific role of IMCs in tumor development, Gr1 + cells were depleted in Tg.AC mice with Gr1 antibody during the first 3 wk of TPA treatment. This treatment significantly (P < 0.05) reduced papilloma formation (Fig. 3 C) . To evalu ate the direct effect of accumulation of IMCs on prolifera tion of keratinocytes, WT and S100A9Tg mice were treated were found in the numbers of papillomas between WT and S100A9KO mice recipients treated with DMBA followed by TPA (Fig. 4 E) . Collectively, these data demonstrate that development of skin tumors directly depends on the accu mulation of granulocytic IMCs in the skin. Next we investi gated the mechanism or mechanisms by which IMCs mediated tumor promotion.
Accumulation of IMCs in skin did not result in immune suppression
We tested the hypothesis that IMCs accumulated in TPA treated S100A9Tg skin had immunesuppressive activity and thus could be defined as MDSCs. S100A9Tg mice were back crossed for nine generations to C57BL/6 mice. Mice were treated for 6 wk with topical application of TPA. Ly6G + granulocytic IMCs were isolated from the skin and were cocultured with splenocytes from OT1 mice stimulated with control or specific peptides. In contrast to the cells with the same phenotype isolated from spleens of tumorbearing mice (MDSCs), skininfiltrating granulocytic cells from TPAtreated mice did not suppress antigenspecific T cell response (Fig. 5 A) . Similarly, Gr1 + CD11b + cells isolated from BM of WT and S100A9Tg mice treated with TPA also lacked immunesuppressive activity (Fig. 5 B) . In contrast, cells with the same phenotype isolated from BM of tumor bearing mice (MDSCs) demonstrated profound suppressive with TPA for 5 wk, and the proportion of proliferating ke ratinocytes (cytokeratin 14 + Ki67 + cells) was evaluated. TPA treatment caused proliferation of keratinocytes in WT mice, which was significantly (P < 0.01) enhanced in S100A9Tg mice (Fig. 3 D) .
To better ascertain the possible role of IMCs in tumor development, we also used mice with targeted deletion of S100A9 (S100A9KO mice, C57BL/6 background; Manitz et al., 2003) . In contrast to FVB/N mice, untreated WT C57BL/6 mice had traces of S100A9 protein in the skin, which was increased after 4 wk of TPA treatment (Fig. 4 A) . S100A9KO mice had no detectable S100A9 protein in the skin (Fig. 4 A) . Treatment of WT C57BL/6 mice with TPA greatly increased the number of Gr1 + myeloid cells in the skin, whereas in S100A9KO mice, this increase was very modest and lower than in WT mice (Fig. 4 B) . In contrast to S100A9Tg mice, S100A9KO mice developed signifi cantly (P < 0.01) fewer skin tumors than their WT C57BL/6 counterparts after treatment with both DMBA and TPA (Fig. 4 C) . Furthermore, mice reconstituted with BM from S100A9KO mice had significantly (P < 0.01) fewer lesions than mice reconstituted with WT BM (Fig. 4 D) , confirming the critical role of BMderived cells in modulating skin tumorigenesis. To further verify a specific role of BMderived cells in tumor development, WT and S100A9 KO mice were reconstituted with BM from WT mice. No differences Each group included four mice (mean and SD are shown). **, P < 0.01. (E) Migration of skin DCs to draining LNs. Dorsal shaved skins of WT and S100A9Tg mice previously treated with acetone or TPA were painted with DDAO, and 24 h later DDAO + CD11c + cells were evaluated in draining LNs by flow cytometry. Each experiment was performed three times. Mean and SD are shown. *, P < 0.05. (F) T cells from OT1 mice were labeled with DDAO fluorescent dye and injected i.v. into TPA-treated WT and S100A9Tg C57BL/6 mice. OVA was applied to the skin 24 h later, and LNs and CD8 + CD45.1 + T cell spleens were evaluated by flow cytometry 3 d after the application. A typical example of the CD8 + CD45.1 + T cell proliferation is shown on the left, and cumulative results (mean ± SD) of three mice in each group are shown on the right. activity (Fig. 5 B) . Because S100A9Tg mice had reduced presence of CD11c + DCs in the skin as compared with WT mice, we analyzed in more detail the different populations of DCs in skin by flow cytometry. Only slight differences between WT and S100A9Tg mice were seen in the propor tion of subsets of skin DCs (Fig. 5 C) , with the exception of CD207 + CD11b  CD103 + DCs, which were significantly ele vated in S100A9Tg mice compared with WT mice (Fig. 5 C) . S100A9Tg had a modestly (P < 0.01) reduced number of Langerhans cells (LCs) in epidermis (Fig. 5 D) . To determine whether those changes would translate into decreased migra tion of DCs to draining LNs, WT and S100A9Tg mice were treated topically with acetone vehicle or TPA for 4 wk, after which the skin was painted with fluorescent dye DDAO. The next day, skindraining LNs were collected and DDAO + DCs were counted. We found significantly lower numbers of DDAO + CD86 + IA bright migratory DCs in LNs of S100A9Tg mice than in WT mice (Fig. 5 E) .
We wondered whether reduction in DC numbers and migration in S100A9Tg skin could result in impaired priming of CD8 + T cells. DDAOlabeled OVAspecific OT1 T cells were transferred to WT or S100A9Tg C57BL/6 mice pre treated for 4 wk with TPA. OVA protein was applied to the same part of the skin as TPA, and 3 d later, proliferation of OT1 T cells was evaluated in LNs and spleen. Robust pro liferation of OT1 cells was observed in all mice. No differ ences were found between WT and S100A9Tg mice (Fig. 5 F) . These results indicate that despite reduced presence of DCs in the skin, antigenspecific response was unaffected in S100A9Tg mice. Together with the data indicating lack of immune suppressive activity of IMCs, this finding suggests that im mune suppression is not the primary reason for increased tumor formation in S100A9Tg mice.
IMCs recruit CD4 + T cells to the skin
We evaluated the presence of lymphocytes in the skin of vehicle and TPAtreated mice. No significant differences between WT and S100A9Tg mice were found in the pres ence of B lymphocytes, NK cells, or CD8 + T cells (not de picted). In contrast, treatment with TPA resulted in the marked accumulation of CD4 + T cells in the skin that was signifi cantly (P < 0.01) higher in S100A9Tg mice than in WT mice (Fig. 6 A) . A small statistically nonsignificant increase was ob served in the population of  T cells (Fig. 6 B) . Conversely, in S100A9KO mice, TPA only caused a modest increase in skin CD4 + T cells as compared with the prominent accumu lation observed in WT C57BL/6 mice ( Fig. 6 C) . Skin CD8 + T cells in both WT and S100A9KO mice were comparably low and unaffected by TPA treatment (not depicted).
The characteristics of CD4 + T cells in skin of TPA treated mice were studied using flow cytometry. Consistent with the data obtained by IHC, the proportion of CD4 + T cells among hematopoietic CD45 + cells in skin was signifi cantly (P < 0.001) higher in S100A9Tg mice than in WT mice (Fig. 6 D) . The prevalence of different subsets within the population of CD4 + T cells in skin was measured using intracellular cytokine staining. No substantial differences were found between WT and S100A9Tg mice in the propor tion of most CD4 + T cell populations. However, S100A9Tg skin showed higher proportions of IL22 + and IL10 + cells and FoxP3 + CD4 + T reg cells and a significantly lower pro portion of IL13 + CD4 + cells than WT skin (Fig. 6 E) . No differences were seen between WT and S100A9Tg skin treated with acetone vehicle alone (not depicted). It was pos sible that although the proportion of cytokineproducing CD4 + T cells was not changed, the level of cytokine produc tion on a per cell basis could be different. However, no dif ferences were found in the fluorescence intensity of those cytokines that showed no changes in the proportion of cells (not depicted). To investigate the ability of IMCs to directly polarize CD4 + T cells in vitro, naive CD4 + CD62L + T cells were cocultured with IMCs isolated from BM of TPA treated WT or S100A9Tg mice. No evidence of CD4 + T cell polarization was found (Fig. 6 F) . Thus, accumulation of IMCs in skin of S100A9Tg mice was associated with sub stantial increase in the presence CD4 + T cells. Gr1 + IMCs and CD4 + T cells localized in the same vicinity in dermis of TPAtreated mice. In contrast,  T cells resided in the dif ferent area of the skin (close to epidermis; Fig. 6 G) . We proposed that although IMCs did not cause specific polariza tion of CD4 + T cells, they could recruit a substantial propor tion of proinflammatory T cell populations. This hypothesis was tested in further experiments.
We investigated whether enhanced tumor formation in S100A9Tg mice was mediated by CD4 + T cells. S100A9Tg;Tg. AC bitransgenic mice were treated with control IgG or CD4specific antibody before and during the first 3 wk of TPA application. CD4 antibody significantly (P < 0.01) re duced the formation of papillomas in these mice (Fig. 7 A) , indicating that the tumorpromoting effect of IMCs is me diated via recruitment of CD4 + T cells. We asked whether depletion of CD4 + T cells could affect TPAinducible accu mulation of IMCs in skin. To address this question, the pres ence of CD4 + T cells and Gr1 + IMCs was evaluated in skin of mice treated with TPA and CD4 antibody for 5 wk. This treatment resulted in abrogation of CD4 + T cell accumula tion but did not affect Gr1 + cells (Fig. 7 B) .
Because IMCs attracted a large number of CD4 + to the skin, even without causing preferential recruitment of T cell populations, the total number of proinflammatory CD4 + T cells in the skin would substantially increase. We asked whether the levels of cytokines produced by CD4 + T cells were different in skin of S100A9Tg and WT mice. The cytokines were also measured in spleen and BM, where no significant changes in myeloid or lymphoid cells were ob served. No differences were found in the amount of IL10 or IL22 between TPAtreated WT and S100A9Tg mice. In contrast, the amount of IL17A was significantly higher in the skin but not spleen and BM of S100A9Tg mice than in WT mice (Fig. 7 C) . CD4 + T cells appear to play a major role in IL17A accumulation in skin because depletion of CD4 + T cells abrogated TPAinducible increase in IL17A in T cell migration. However, IMCs activated with LPS or TPA secreted potent chemotactic activity for CD4 + T cells (Fig. 8 A and not depicted) . Importantly, chemotaxis of CD4 + T cells was observed only if T cells were also stimulated be fore the assay (Fig. 8 A) . When IMC supernatants were placed in both chambers during the assay, CD4 + T cell migration was significantly reduced, indicating that the effect was indeed the result of chemotaxis (not depicted).
Using RNA isolated from skin, we examined expression of chemokines known to be involved in the migration of CD4 + T cells. Expression of ccl3 (chemokine [C-C motif] ligand 3) and ccl4 RNAs was significantly (P < 0.05) upregulated in the skin of TPAtreated S100A9Tg mice compared with WT mice, whereas the expression of ccl22 was modestly increased the skin (Fig. 7 D) . These data suggested that IL17 could play an important role in IMCmediated promotion of tumor formation. To test this hypothesis, we used IL17 neutraliz ing antibody in C57BL/6 S100A9Tg and WT mice treated with DMBA and TPA. Blockade of IL17 dramatically reduced papilloma formation in S100A9Tg mice (Fig. 7 E) . Thus, accumulation of granulocytic IMCs in skin resulted in recruitment of CD4 + T cells and to a lesser extent  T cells that could promote tumor development via release of IL17.
The mechanism of IMC-inducible recruitment of CD4 + T cells
How could IMCs recruit CD4 + T cells? We evaluated the ability of IMCs to attract CD4 + cells in vitro. Supernatants from normal BMderived IMCs had no effect on CD4 + The presence of CD4 + T cells and Gr-1 + IMCs in skin of C57BL/6 S100A9Tg mice treated with TPA and CD4 antibody for 5 wk. Cells were evaluated by IHC (n = 4). (C) The presence of cytokines in tissues of WT and S100A9Tg mice treated with TPA for 6 wk. Cytokines were measured in whole cell lysates using ELISA. **, P < 0.01. (D) The amount of IL-17A in skin of mice described in B measured by ELISA. (B and D) **, P < 0.01 from acetone-treated mice; #, P < 0.05 from TPA only-treated mice (n = 6). (E) Papilloma formation in S100A9Tg C57BL/6 mice was induced by DMBA application, followed by 16 wk of treatment with TPA. Mice were treated with 200 µg of either control IgG or neutralizing IL-17 antibody during the first 12 wk. Each group included five mice. Two-way ANOVA, P < 0.001. (B-E) Mean and SD are shown.
CCL4, this chemokine was measured in supernatants from BM IMCs isolated from TPAtreated WT and S100A9Tg mice. A large amount of CCL4 was found in supernatants from stimulated IMCs (Fig. 8 E) . Next, we evaluated the na ture of stimuli that could induce expression of ccl4 in IMCs isolated from BM of naive mice. IMCs were treated for 24 h with several proinflammatory cytokines. IFN caused more than fourfold upregulation of ccl4 expression. The effect of TNF was significant but less potent, whereas IL1 at a selected concentration did not upregulate ccl4 expression in (Fig. 8 B) . However, no differences in the amount of CCL3 and CCL22 proteins were found in skin lysates of TPA treated S100A9Tg and WT mice (Fig. 8 C) . In contrast, the amount of CCL4 in the skin of TPAtreated S100A9Tg mice was significantly higher than in WT mice. No differences in the amount of CCL4 were observed in spleens, BM, lung, or liver (Fig. 8 D) . Because skin was the primary site of IMC accumulation in TPAtreated S100A9Tg mice, these data are consistent with the role of IMCs as the primary source of CCL4. To verify that IMCs are indeed able to produce The range of most commonly used concentrations was tested. Concentrations shown: 250 ng/ml IFN-, 50 ng/ml TNF, 50 ng/ml IL-1, and 100 ng/ml LPS. Ccl4 expression was measured by quantitative PCR and normalized to -actin. Mean and SD are shown. *, P < 0.05; **, P < 0.01; ***, P < 0.001 from control (n = 3). (G) Expression of ccl4 in Gr-1 + and Gr-1  cells isolated from skin of WT or S100A9Tg mice treated for 5 wk with TPA (n = 3). Mean and SD are shown.
were performed in S100A9Tg;Tg.AC bitransgenic mice who developed higher numbers of papillomas than Tg.AC mice, but the CCL4 antibody still drastically (P < 0.01) reduced the number of tumors (Fig. 9 E) .
DISCUSSION
In this study, we report, for the first time, that granulocytic IMCs directly contribute to skin tumor development via recruitment of IL17-producing CD4 + T cells (Th17 cells). Although the link between inflammation and cancer is well established (Arthur et al., 2012; Coussens et al., 2013) , the contribution of specific cell populations to the initial phase of tumor development remains unclear. Previously, Ms were shown to be involved in early stages of tumor development and progression (Hagemann and Balkwill, 2005; Sica and Bronte, 2007; Schmid and Varner, 2012) . The role of MDSCs in tumor immune escape is now well established. In recent years, evidence pointed to expansion of MDSCs in chronic infection and inflammation (Cuenca et al., 2011; Nagaraj et al., 2013) . This increase in MDSCs raised the question as to whether these cells could contribute to tumorigenesis. Our data demonstrated accumulation of a large number of CD33 + S100A9 + cells (the phenotype typical for MDSCs) in IMCs (Fig. 8 F) . We assessed the expression of ccl4 in cells isolated directly from skin of WT or S100A9Tg mice. Skin Gr1 + IMCs from TPAtreated WT or S100A9Tg mice expressed a high level of ccl4, whereas no expression was detected in Gr1  cells (Fig. 8 G) .
To verify the role of CCL4 in CD4 + T cell recruitment by Gr1 + myeloid cells, we added neutralizing CCL4 anti body to IMC supernatants in chemotaxis assay. CCL4specific antibody abrogated CD4 + T cell migration caused by IMCs in a dosedependent manner (Fig. 9 A) . To test the role of CCL4 in vivo, WT and S100A9Tg mice were treated for 4 wk with control or CCL4 antibody concurrent with TPA. Treatment with CCL4 antibody did not affect the presence of Gr1 + myeloid cells or CD8 + T cells in the skin (not depicted). In contrast, neutralization of CCL4 significantly (P < 0.01) reduced the presence of CD4 + T cells in WT and S100A9Tg skin (Fig. 9 B) . CCL4 antibody significantly re duced the presence of IL17A in the skin of S100A9Tg mice, strongly suggesting the link between CCL4mediated CD4 + T cell migration and IL17A presence in the skin (Fig. 9 C) . Weekly treatment of Tg.AC mice with CCL4 antibody dur ing the first 3 wk of TPA promotion significantly reduced the formation of tumors (P < 0.01; Fig. 9 D) . Similar experiments papilloma formation. We found that granulocytic IMCs recruited CD4 + T cells to the site of their accumulation. Im portantly, only activated IMCs were able to recruit CD4 + T cells. Our data indicated that IMCs did not specifically re cruit Th17 CD4 + T cells or cause their conversion from pre cursors, but rather recruited these cells as part of large pool of CD4 + T cells. It was associated with dramatic decrease in IL 13-producing CD4 + T cells. IL13 was previously shown to be a negative regulator of Th17 cells (Newcomb et al., 2009 ). This resulted in significant increase of IL17 but not IL22 in the skin of S100A9Tg mice as compared with WT mice. Depletion of CD4 + T cells or IL17 in S100A9Tg mice ab rogated induction of papilloma formation. These data strongly indicate that CD4 + T cells and IL17 mediated the effect of IMCs on tumor development.
The role of CD4 + T cells in tumor progression remains enigmatic and thus requires further investigation. The CD4 + T cell deficiency on one hand enhanced cancer progression in methylcholanthrene (MCA)initiated sarcoma development (Koebel et al., 2007; DeNardo et al., 2010) , whereas on the other hand, it inhibited tumor development in the twostage squamous carcinogenesis model (Girardi et al., 2003) . Sim ilarly, in the K14HPV16 skin cancer model, with E6/E7 oncogenes expressed in epidermis from keratin 14 promoter, CD4 + T cell deficiency modestly attenuated neoplastic pro gression, whereas cervical carcinoma development was sig nificantly enhanced (Daniel et al., 2003 (Daniel et al., , 2005 . However, there are studies suggesting that IL17 and IL22 produced by Th17 cells contribute to tumor development by inducing an giogenesis or directly affecting keratinocyte proliferation and survival (Heidenreich et al., 2009; Cho et al., 2012; Fujita, 2013) . IL17 also promotes accumulation of cells with MDSC phenotype (He et al., 2010) , suggesting a feedback mecha nism. IL17 KO mice in a twostage carcinogenesis model showed delayed papilloma formation compared with WT mice (Xiao et al., 2009; Wang et al., 2010) .
We identified CCL4 chemokine as the main factor responsible for IMCmediated recruitment of CD4 + T cells. CCL4 or MIP1 is a 69aa member of the  (CC) family of chemokines. It is produced by various cells, including myeloid cells, and binds to CCR1, CCR5, and US28 recep tors. Melanomaassociated MDSCs produce high levels of CCL4 among other chemokines, and in CCR5deficient mice growth of transplantable tumors was delayed (Schlecker et al., 2012) . Activated CD4 + T cells upregulate CCR5 receptor, allowing these cells to be recruited to the site of CCL4 pro duction (Castellino et al., 2006) , which is consistent with our finding that IMCs attracted only activated CD4 + T cells. Al though it was reported that different CD4 + T cell subsets may express unique repertoires of chemokine receptors, current evidence suggests that CCR5 can be expressed on recently activated cells of any subset (Bromley et al., 2008) , consistent with lack of preferential accumulation of specific populations of CD4 + T cells in the skin of S100A9Tg mice.
Our data suggest a sequence of events that promote tumor formation in skin and possibly other tissues. Granulocytic tissues of patients with inflammatory conditions, which pre disposes to the development of cancers. Accumulation of these cells was more prominent than that of mature neutrophils and Ms.
Because inflammation is a complex process, the specific role of individual cell populations in tumor promotion is dif ficult to ascertain. S100A9Tg mice provide a novel experi mental model in which tissue accumulation of cells with the IMC phenotype is not caused by infection, trauma, or can cer. The vast majority of myeloid cells accumulated in skin of S100A9Tg were granulocytic IMCs, which is consistent with the concept that overexpression of S100A9 in myeloid precursors inhibits differentiation of myeloid precursors to DCs, and to some extent Ms, and promotes appearance of immature granulocytes. Activated keratinocytes can attract granulocytes via release of CXCL8 chemokine (Huang et al., 2011) . This chemokine may provide a signal for initial influx of IMCs to TPAtreated skin. Our results with BM trans fers and Gr1-specific antibody depletions in S100A9Tg mice, as well as decreased skin carcinogenesis in S100A9KO mice, demonstrate that IMCs were the primary facilitator of tumor development in this experimental system. Our data in S100A9KO mice are not consistent with a recent study indi cating that S100A9 had a protective role in inflammation induced skin carcinogenesis (McNeill and Hogg, 2014) . Whether differences were caused by differences in the mouse models or other factors needs to be elucidated. IMCs accu mulated in skin of mice lack immunesuppressive activity and thus cannot be defined as MDSCs. These results were consis tent with recent findings of accumulation of myeloid cells with a phenotype similar to that of MDSCs but lacking immunesuppressive activity in mice exposed to cigarette smoke (Ortiz et al., 2014) . These cells acquired immunesuppressive activity only after the development of lung tumors (Ortiz et al., 2014) . Our data demonstrated that although the num ber of DCs migrating from skin to LN in S100A9Tg mice was decreased, the priming of CD8 + T cells to antigen ap plied over the skin was not affected. Apparently, the modest decrease in DCs in skin was not sufficient to inhibit CD8 + T cell priming. Alternatively, the significantly higher propor tion of CD11b  CD207 + CD103 + DCs in S100A9Tg mice may have compensated for decrease of other DC subsets because these cells play a major role in crosspresentation of antigens in the skin (Henri et al., 2010) . Collectively, these data indicate that enhanced papilloma formation in S100A9Tg mice is not caused by myeloid cell-mediated immune sup pression as typically observed with MDSCs in cancer.
Granulocytic cells may contribute to neoplastic transfor mation by increasing the rate of mutation and proliferation of epithelial cells via release of reactive oxygen species (Marnett, 2000; Le'Negrate et al., 2003; Balkwill, 2009) , activation of cyclooxygenase2 (Kim et al., 2005) , and inhibition of nucle otide excision repair by myeloperoxidase (Gasche et al., 2001; Hofseth et al., 2003; Güngör et al., 2007) . In this study, we did not evaluate the malignant conversion of tumor lesions but focused on the earlier premalignant events promoting described (Gebhardt et al., 2008) . Papillomas were assessed weekly and counted when they reached 1 mm for at least 2 wk. In BM transfer experiments, le thally irradiated (950 rads) mice were injected i.v. with 10 6 BM cells from donor mice. Treatment with TPA or DMBA plus TPA as described above was started 3 wk after the BM transfer.
Tissue preparation and histology. Skin pieces were snapfrozen, and slides were fixed with acetone and blocked overnight with 10% goat serum, 1% BSA, and 2.5% mouse serum in PBS at room temperature. The primary antibodies from BD were used at 1:100 dilutions: Gr1 (RB68C5), CD4 (H129.19), and CD8 (536.7). The antibodies from eBioscience were used at 1:50 dilution: CD11c (N418) and F4/80 (BM8). Biotinylated anti-rat IgG (Vector Laboratories) or anti-hamster IgG (Vector Laboratories) was used as a secondary antibody. Alkaline phosphatase kit and Vector Red substrate (Vector Laboratories) were used for visualization of the results. The tissues were counterstained with hematoxylin. Images were taken by the digital slide scanner Scanscope (Aperio) and analyzed by Aperio software. Cell number was calculated per 1 mm 2 . The antibodies specific for  T cells (GL3), cy tokeratin14 (LL002), and Ki67 (SP6) were purchased from Abcam, and the staining was evaluated on an E600 upright microscope.
Cytokine expression. For the analysis of gene expression, total RNA was extracted with TRIzol reagent (Invitrogen), and cDNA was synthesized using the High Capacity cDNA Reverse transcription kit (Applied Biosys tems). To detect chemokines, PCR was performed with 2 µl cDNA and 12.5 µl SYBR Master Mixture (Applied Biosystems) using specific primers: Ccl2, 5CCCAATGAGTAGGCTGGAGA3 and 5AAAATGGATCCAC ACCTTGC3; Ccl3, 5CCAAGTCTTCTCAGCGCCATA3 and 5GATGAATTGGCGTGGAATCTTC3; Ccl4, 5TGCTCGTGG CTGCCTTCT3 and 5CTGCCGGGAGGTGTAAGAGA3; Ccl5, 5TGCCCACGTCAAGGAGTATT3 and 5CAGGACCGGAGT GGGAGTA3; Ccl9, 5GATGAAGCCCTTTCATACTGC3 and 5GTGGTTGTGAGTTTTGCTCCAATC3; and Ccl22, 5GTGGC TCTCGTCCTTCTTGC3 and 5GGACAGTTTATGGAGTAGCTT3. Amplification of endogenous actin was used as an internal control.
For evaluation of the proteins, tissues were homogenized in RIPA buf fer, and BM cells were flushed out for protein extraction. Chemokines were measured by ELISA using the kits from PeproTech: CCL3, CCL4, or CCL22. CCL4 was also measured using an R&D Systems kit. Likewise, the cytokines (IL10, IL17A, and IL22) in skin, spleen, and BM were measured by ELISA using the kits from eBioscience.
Western blot. Samples (30 µg protein per lane) were subjected to electro phoresis in 12% SDSpolyacrylamide gels and then blotted onto PVDF membranes. Membranes were blocked for 1 h at room temperature with 5% dry skim milk in TBS (20 mM TrisHCl, pH 7.6, and 137 mM NaCl plus 0.1% [vol/vol] Tween 20) and then probed with S100A9 or actin-specific antibodies (Santa Cruz Biotechnology, Inc.), followed by secondary anti body conjugated with horseradish peroxidase. Results were visualized by chemiluminescence detection (GE Healthcare).
Depletion of cells and neutralization of chemokines in vivo.
Mice were injected i.p. with 250 µg CD4 (clone: GK1.5; Bio X Cell) and Gr1 (clone: RB68C5; Bio X Cell). Injections were performed once a week for 4 wk starting 1 wk before the beginning of TPA treatment. For neutralization of CCL4 and IL17A, 100 µg CCL4 (R&D Systems) or 200 µg IL17A (clone: 17F3; Bio X Cell)-specific monoclonal antibodies were used. Control groups in CD4 and Gr1 depletion and neutralization experiments received rat IgG2b isotype (clone: LTF2; Bio X Cell); controls for IL17A neutralization experiments received mouse IgG (SigmaAldrich), whereas controls in CCL4 neutralization experiments received goat IgG (R&D Systems). CD4 + T cell polarization experiments. Naive CD62L + CD4 + T cells were isolated from spleen of FVB/N mice using magnetic beads (Miltenyi Biotec) and coculture with Gr1 + cells isolated from BM of WT or S100A9Tg
IMCs accumulate at the site of cutaneous irritation or inflam mation. Activated IMCs release CCL4 that recruits CD4 + T cells, including proinflammatory populations. These T cells release IL17 to stimulate proliferation of keratinocytes, which contribute to tumor formation. The direct effect of IMCs on keratinocytes or epithelial cells in other tissues merits further investigation, as well as the possibility that targeting IMCs may benefit individuals with high risk of cancer development.
MATERIALS AND METHODS
Patient samples. Deidentified colon tissues slides were obtained from St. Mark's Hospital (Harrow, England, UK). Samples were taken from patients after obtaining informed consent and with the approval of the Outer West London Research Ethics Committee (UK). It included six samples obtained from normal colonic biopsies (control), five samples from patients with ul cerative colitis showing low and highgrade dysplasia, and six samples from patients with colorectal cancer (moderately differentiated adenocarcinoma). Paraffinembedded tissue blocks were retrieved using an approved Insti tutional Review Board protocol for deidentified archived skin biopsies through the Department of Dermatology, National Institutes of Health Skin Disease Research Center Tissue Acquisition Core (P30AR057217), Perelman School of Medicine, University of Pennsylvania (Philadelphia, PA). It in cluded five samples from normal skin (control), five samples from patients with lichen planus, five patients with psoriasis, five patients with spongiotic der matitis (eczema), five patients with BCC, and five patients with melanoma.
After deparaffinization, rehydration, and blocking endogenous perox ides with fixation with 5% hydrogen peroxide in methanol, heatinduced antigen retrieval was performed using TrisEDTA buffer. For evaluation of S100A9 + CD33 + cells, tissues were stained with S100A9 antibody (diluted 1:500 in 5% BSA; Novus Biologicals) and CD33 antibody (dilution 1:100 in 5% BSA; Novocastra) followed by Alexa Fluor 594 antibody (dilution 1:400 in 5% BSA; Life Technologies) and Alexa Fluor 647 antibody (dilu tion 1:400 in 5% BSA; Life Technologies). For neutrophils and Ms, a single staining protocol was used. Neutrophils were stained with neutrophil elastase antibody (dilution 1:2,000 in 5% BSA; Abcam) and Ms with CD163 antibody (dilution 1:200 in 5% BSA; Abcam). Alexa Fluor 594 (Life Technologies) anti-rabbit antibody was used as secondary. Cell nuclei were stained with DAPI (dilution 1:5,000 in PBS; Life Technologies). Cells were analyzed using a TCS SP5 confocal microscope (Leica) and E600 upright microscope (Nikon). The number of cells per square millimeter of tissue was calculated in at least five fields using Image pro plus software (Media Cybernetics). Positive stained cells were normalized to total nuclear cell count using DAPI.
Mice. All animal experiments were approved by the University of South Florida Institutional Animal Care and Use Committee. Mice were housed in pathogenfree facilities. Tg.AC mice described previously (Tepper et al., 1990) were obtained from Taconic. S100A9Tg mice on FVB/N background (Cheng et al., 2008) and S100A9KO mice on C57BL/6 background (Manitz et al., 2003) were described previously. BALB/c, C57BL/6, and FVB/N mice were obtained from the National Cancer Institute, and OT1 mice were obtained from the Jackson Laboratory. In S100A9Tg;Tg.AC bitransgenic mice, the presence of S100A9IRESGFP transgene was verified by the expression of GFP in leukocytes from peripheral blood, and the v-h-ras transgene was detected by genomic PCR for the SV40 sequences. In some experiments, S100A9Tg mice on C57BL/6 background were used after backcrossing S100A9Tg FVB/N mice with C57BL/6 mice for nine generations.
Skin carcinogenesis. Female, agedmatched (7-10 wk old) littermate mice were used in experiments with Tg.AC and S100A9Tg;Tg.AC mice. Dorsal skin was shaved, and 3 nmol TPA (SigmaAldrich) in 200 µl acetone vehicle was applied twice a week for 4 or 6 wk. In the carcinogenesis model in C57BL/6 WT or S100A9KO mice, 100nmol single dose of DMBA was topically applied, followed by 10 nmol TPA every 24 h for 12 wk, as previously For the assessment of in vivo T cell proliferation in response to antigens, splenocytes and LN cells collected from OT1 CD45.1 + mice were labeled with 5 µM DDAO. Eight million DDAOlabeled OT1 cells were injected into the tail vein of C57BL/6 (CD45.2 + ) WT and S100A9Tg mice that were pretreated for 4 wk with TPA. The day after transfer, 10 mg OVA protein in 500 µl Ultrasicc gel was applied onto the shaved dorsal skin of the mice. 3 d later, skindraining LNs and spleen were collected. Cells were stained and analyzed by flow cytometry.
Statistical analysis. Statistical analysis was performed using an unpaired twotailed Student's t test with significance determined at P < 0.05. For the analysis of papilloma formation, statistical significance of repeated measure ments was assessed using a twoway ANOVA test.
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Skin cell isolation and analysis. Pieces of shaved skin were incubated in PBS containing 0.2% trypsin for 30 min at 37°C, cut into small pieces, and incubated with 0.8 mg/ml collagenase in RPMI for 40 min at 37°C. Single cell suspension was prepared by pressing tissues through a 100µm cell strainer. For analysis of the cell phenotype, cells were used directly for flow cytometry. Nonspecific staining was blocked by Fcblock (BD), and staining was performed in 1% FBS. The cells were analyzed by flow cytometry using an LSRII cytometer (BD) and FlowJo software (8.6). Dead cells were excluded by DAPI staining, and CD45 + cells were analyzed. For the analysis of intracellular cytokines, mononuclear cells were isolated by density cen trifugation on FicollPaque, washed, and plated at 2 × 10 6 /ml concentration in roundbottom 96well plates. Cells were then stimulated with 30 ng/ml TPA and 750 ng/ml ionomycin for 4 h, the last 3 h in the presence of GolgiStop. Cells were stained by LiveDead Violet (Life Technologies), followed by CD45 and CD4 antibodies. After fixation and permeation, cells were stained for intracellular cytokines or FoxP3 and analyzed by flow cytometry. For the isolation of myeloid cells from skin, the shaved skin was cut and washed with PBS buffer. The subcutaneous fat was scrapped off using a scalpel, and the skin tissue was divided into three to four pieces. The epidermis and dermal layer were enzymatically digested and subsequently dissociated into single cell suspension using a gentleMACS dissociator (Milte nyi Biotec). IMCs were purified from single cell suspension using biotinylated anti-Gr1 antibody (Miltenyi Biotec), followed by streptavidin microbeads. Ly6G + granulocytic IMCs were isolated from the skin using the Epidermis Dissociation kit (Miltenyi Biotec).
Chemotaxis. Gr1 + cells were isolated from BM using biotinylated antiGr1 antibody and streptavidin microbeads (Miltenyi Biotec). The purity of Gr1 + CD11b + cells was >95%. Cells were cultured overnight in serumfree medium (Cellgenix) at 10 6 /ml, in the presence or absence of 0.5 µg/ml LPS. Supernatants were collected after 24 h and added at 30% vol/vol to the bottom chamber of Transwell plates (5µm pores) in a total volume of 500 µl serum free medium. To activate T cells, splenocytes were cultured with 0.5 µg/ml antiCD3 antibody for 3 d in serumfree medium. One million stimulated or nonstimulated splenocytes were resuspended in 100 µl serumfree me dium and added to the top chamber of the Transwell. After 4h incubation at 37°C, CD4 + T cells that passed through the membrane to the lower chamber were measured by flow cytometry.
LC staining. Epidermal sheets were prepared from dorsal skin as previously described (Gabrilovich et al., 1994) . The epidermal sheets were fixed in ace tone for 1 min, blocked with 1% BSA and Fcblock, and stained overnight at 4°C with IA/IEPE antibody (clone 2G9; BD) at 1:100 dilution. The next day, sheets were washed, stained with secondary antibody, and mounted on slides. The staining was analyzed in an SP5 confocal microscope.
DC migration and T cell proliferation. Shaved dorsal skin was painted with 0.4 ml of a 1:1 mixture of acetone/DBP containing 250 µM DDAO (Invitrogen). 24 h later, draining LNs were collected and treated with 1 mg/ml collagenase in PBS/BSA for 30 min, and single cell suspensions were stained and analyzed by flow cytometry. For the analysis of in vitro cell proliferation, 10 5 splenocytes from BALB/c mice (responders) were mixed with 10 5 T cell-depleted and irradiated (20Gy) splenocytes from FVB/N mice (stimulators) in Ubottom 96well plates. Gr1 + cells from TPAtreated S100A9Tg or WT mice were added into wells at dif ferent ratios. On day 4, cells were pulsed with [ 3 H]thymidine (1 µCi/well; GE Healthcare) for 18 h. [ 3 H]thymidine uptake was counted using a liquid scintillation counter and expressed as counts per minute.
